

Accepted Manuscript

Hypoxia Enhances CD8⁺ Tc2 Dependent Airway Hyperresponsiveness and Inflammation Through Hypoxia Inducible Factor 1 α

Fangkun Ning, PhD, Katsuyuki Takeda, MD, PhD, Michaela Schedel, PhD, Joanne Domenico, BS, Anthony Joetham, BS, Erwin W. Gelfand, MD



PII: S0091-6749(19)30030-2

DOI: <https://doi.org/10.1016/j.jaci.2018.11.049>

Reference: YMAI 13830

To appear in: *Journal of Allergy and Clinical Immunology*

Received Date: 2 February 2018

Revised Date: 21 November 2018


Accepted Date: 30 November 2018

Please cite this article as: Ning F, Takeda K, Schedel M, Domenico J, Joetham A, Gelfand EW, Hypoxia Enhances CD8⁺ Tc2 Dependent Airway Hyperresponsiveness and Inflammation Through Hypoxia Inducible Factor 1 α , *Journal of Allergy and Clinical Immunology* (2019), doi: <https://doi.org/10.1016/j.jaci.2018.11.049>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Hypoxia Enhances CD8⁺ Tc2-Mediated Allergen Triggered Experimental Asthma



	Normoxia	Hypoxia
pSTAT6	+	+++
GATA3	+	+++
HIF1 α Gene Expression	+	+
HIF1 α Stabilization	-	+
IL-13	+	+++
Eosinophilia	+	+++
AHR	+	+++

IL-4: Interleukin 4
 IL-13: Interleukin 13
 JAK1/3: Janus kinase 1/3
 pSTAT6: Phospho signal transducer and activator of transcription 6
 HIF1 α : Hypoxia-inducible factor 1-alpha
 Gata3: GATA binding protein 3
 AHR: Airway hyperresponsiveness

**Hypoxia Enhances CD8+ Tc2 Dependent Airway Hyperresponsiveness and
Inflammation Through Hypoxia Inducible Factor 1 α**

Fangkun Ning PhD¹, Katsuyuki Takeda MD, PhD¹, Michaela Schedel PhD¹, Joanne
Domenico BS¹, Anthony Joetham BS¹, Erwin W. Gelfand MD^{1*}

¹Division of Cell Biology, Department of Pediatrics, National Jewish Health,
1400 Jackson Street, Denver, Colorado 80206, USA

***Corresponding Author:**

Erwin W. Gelfand, M.D.
Department of Pediatrics
National Jewish Health
1400 Jackson Street
Denver, CO 80206, USA
Phone: (303) 398-1196
Fax: (303) 270-2105
E-mail: erwin3460@gmail.com

Funding Support: This work was supported by NIH grants HL-36577 and AI-77609 (to
EWG) and the Joanne Siegel Fund. FN and MS were supported by the Eugene F. and
Easton M. Crawford Charitable Lead Unitrust, Pohs, and Dreizzasun funds. The content
is solely the responsibility of the authors and does not necessarily represent the official
views of the NHLBI or the NIH.

27 **Conflict of Interest statement:** The authors declare no relevant conflicts of interest.

Abstract

Background: CD8⁺ T cells (Tc2) become potent, steroid-insensitive pathogenic effector cells in experimental asthma undergoing transcriptional reprogramming to IL-13 production in the presence of IL-4. However, no studies have described the effects of hypoxia exposure on Tc2 differentiation.

Objective: We determined the effects of hypoxia exposure on IL-13-producing CD8⁺ Tc2 cells.

Methods: CD8⁺ transgenic OT1 cells, differentiated with IL-2 and IL-4 (Tc2 cells) were exposed to normoxia (21% O₂) or hypoxia (3% O₂) and IL-13 production *in vitro* was monitored. Following differentiation under these conditions, cells were adoptively transferred into CD8-deficient mice and lung allergic responses including airway hyperresponsiveness to inhaled methacholine were assessed. The effects of pharmacologic inhibitors of hypoxia inducible factor 1 α (HIF-1 α) and HIF-2 α were determined as were responses in HIF-1 α -deficient OT1 cells.

Results: Under hypoxic conditioning, CD8⁺ Tc2 differentiation was significantly enhanced with increased numbers of IL-13⁺ T cells and increased production of IL-13 *in vitro*. Adoptive transfer of Tc2 cells differentiated under hypoxia restored lung allergic responses in sensitized and challenged CD8-deficient recipients to a greater degree than seen in recipients of Tc2 cells differentiated under normoxia. Pharmacologic inhibition of HIF-1 α or genetic manipulation to reduce HIF-1 α expression reduced the hypoxia-enhanced differentiation of Tc2 cells, IL-13 production, and the capacity of transferred cells to restore lung allergic responses *in vivo*. IL-4-dependent, hypoxia-

mediated increases in HIF-1 α and Tc2 differentiation were shown to be mediated through activation of JAK1/3 kinase and GATA3.

Conclusions: Hypoxia enhances CD8⁺ Tc2-dependent airway hyperresponsiveness and inflammation through activation of HIF-1 α . These findings coupled with the known insensitivity of CD8⁺ T cells to corticosteroids suggests that activation of the IL-4-HIF-1 α -IL-13 axis may play a role in the development of steroid-refractory asthma.

Capsule summary: Hypoxia exposure amplifies CD8⁺ Tc2 differentiation with increased release of IL-13 *in vitro* and augmentation of lung allergic responses *in vivo*. The increases in Tc2 differentiation under hypoxia were shown to be dependent on HIF-1 α .

Clinical implications: Airway inflammation can trigger the hypoxia response pathway with induction of HIF-1 α expression. The combination of CD8⁺ Tc2 cells, activation of the hypoxia response pathway and HIF-1 α upregulation may contribute to steroid-refractory asthma.

Key words: Asthma, CD8⁺ T cells, hypoxia, IL-13, HIF-1 α

73 **Abbreviations used:**

74 AHR: Airway hyperresponsiveness

75 BAL: Bronchoalveolar lavage

76 DEX: Dexamethasone

77 GATA3: GATA Binding Protein 3

78 HIF-1 α : Hypoxia inducible factor 1 α

79 IFN γ : Interferon- γ

80 IL: Interleukin

81 JAK: Janus kinase

82 KO: Knock out

83 OVA: Ovalbumin

84 PAS: Periodic acid–Schiff

85 pSTAT6: Phospho Signal transducer and activator of transcription 6

86 Tc2: Type 2 cytotoxic T cells

87

Introduction

Asthma is a complex clinical syndrome characterized by airway inflammation, airway hyperresponsiveness (AHR), and airflow obstruction. This complexity is underscored by the number of cell types, mediators, and pathways linked to the disease. A major advance in the treatment of asthma was achieved with the regular use of inhaled corticosteroids (ICS) as a controller medication. Nevertheless, despite diligent compliance and technique, a large percentage of patients with asthma fails to achieve control of their disease with current therapies ¹. A subset of patients with a limited response to ICS has been defined as severe asthma ², considered here as steroid-resistant (SR) asthma. Little is understood regarding the underlying mechanisms or pathways (endotypes) responsible for SR asthma and it is likely that many factors impede the achievement of asthma control. Defining the underlying mechanism(s) of SR asthma is a priority but few such endotypes have been well characterized ³⁻⁵. One endotype, characterized by airway eosinophilia, CD4⁺ Th2 cytokine production, and steroid responsiveness has been best studied ⁶. In contrast, asthma associated with prominent airway neutrophilia has been associated with steroid resistance ⁷⁻⁹. Neutrophils, unlike eosinophils, fail to undergo apoptosis in the presence of corticosteroids ⁹. Other cell types including mast cells and basophils, Th17 cells, and even some innate lymphocytes (ILCs) may be similarly insensitive to corticosteroids ¹⁰⁻¹², linking disease where these cells are prominent in the airways to SR asthma.

Accumulating evidence from studies of animal models and severe asthmatics has identified the prominence of a subset of CD8⁺ T cells in the airways and epithelium which may contribute to steroid-insensitivity and the pathophysiology of severe or fatal

asthma¹³⁻¹⁵. These CD8⁺ T lymphocytes, unlike CD4⁺ T cells, are refractory to corticosteroids¹⁶ and have the capacity to undergo transcriptional reprogramming from a Tc1-IFN γ - to a Tc2-IL-13-producing lymphocyte subset¹⁷. Numbers of these CD8⁺ T cells correlated with reduced lung function and basement membrane thickening¹⁸⁻²¹. Moreover, increased numbers of CD8⁺ T cells have been demonstrated in lung tissues following a fatal asthma attack²². In severe asthmatics, increased numbers of IL-13⁺CD8⁺ T cells have also been shown²⁰. Central to CD8⁺ T cell reprogramming to IL-13 production was IL-4, which triggered a cascade of transcriptional events culminating in IL-13 production¹⁷.

Low oxygen tension in tissues (hypoxia) occurs in many pathological conditions including chronic inflammation and promotes expression of genes through post-translational modifications and stabilization of the α subunits (HIF-1 α and HIF-2 α) of hypoxia-inducible factors (HIFs)²³. Although there is growing evidence that HIFs contribute to the pathophysiology of asthma^{24, 25}, little is known about HIFs in the regulation of lung allergic immune responses. Hypoxia has often been considered to be an inhibitor of T lymphocyte function, although active and robust T cell responses occur at many hypoxic inflammatory sites^{26, 27}. Hypoxia-related pathways have been shown to facilitate differentiation of CD8⁺ cytotoxic T cells leading to enhanced clearance of chronic virus infection and tumor cells²⁸. Such findings indicate that in contrast to inhibition of some T cell functions, hypoxia exposure may enhance the functional differentiation of certain T cell subsets. Since HIF-1 α expression was increased following ligation of the T cell receptor²⁹, we determined whether hypoxia enhanced transcriptional reprogramming in CD8⁺ T cells through a HIF-dependent pathway.

134 Further, we defined a role for hypoxia and HIF-1 α in the enhanced reprogramming of
135 CD8⁺ T cells to pathogenic IL-13-producing effector cells.

136

137

Materials and Methods

Animals

OT-1 TCR transgenic (OT-1) mice, Lck-Cre/OT-1, Lck-Cre/HIF-1 α^{flox} /OT-1 and homozygous CD8-deficient mice were bred in the animal facility at National Jewish Health (Denver, CO). OT-1 mice (C57BL/6 background) express a transgenic TCR specific for SIINFEKL peptide (OVA₂₅₇₋₂₆₄)¹⁷. Lck-Cre/OT-1 mice were F2 progeny of Lck-Cre mice and OT-1 mice. Lck-Cre/HIF-1 α^{flox} /OT-1 mice were F2 progeny of Lck-Cre/HIF-1 α^{flox} mice (provided by Dr. Holger Eltzschig, University of Colorado Denver, Aurora, CO)³⁰ and OT-1 mice. CD8-deficient mice were generated by targeting the CD8 α chain gene in C57BL/6 mice³¹. Animal experiments in this study were conducted under a protocol approved by the Institutional Animal Care and Use Committee of National Jewish Health.

CD8+ T cell culture

CD8+ effector memory T cells were generated *in vitro* as described previously^{17, 32, 33}. In brief, mononuclear cells were harvested from the spleens of OT-1 mice, followed by stimulation with 1 $\mu\text{g/mL}$ SIINFEKL peptide (GenScript, Piscataway, NJ) for 1.5 hrs (20×10^6). Two days after culture, living cells were re-isolated using Histopaque (Sigma, St. Louis, MO) and cultured in complete RPMI medium 1640 that contained recombinant mouse IL-2 (20 ng/mL) (Peprotech, Rocky Hill, NJ) or IL-2+IL-4 (20 ng/mL) (Peprotech). For HIF inhibition experiments, DMSO, 1 μM BAY 87-2243 (Selleck Chemicals, Houston, TX) or 10 μM HIF-C2 (Xcessbio Biosciences, San Diego, CA) were added into the medium together with IL-2 or IL-2+IL-4. Cells were either cultured in

a CO₂ incubator in a normoxia (21% O₂+5% CO₂) or hypoxia chamber (3% O₂+5% CO₂) at 37°C. Cytokines and inhibitors were changed every day for a further 4 days of culture. During hypoxia conditioning, O₂ and CO₂ levels were controlled by Proox C21 (BioSpherix, Lacoma, NY). For JAK inhibition experiments, DMSO, or 25, 50, or 100 nM of the inhibitor R256 (Rigel Pharmaceuticals, South San Francisco, CA) was added to the medium together with IL-2+IL-4. R256 was shown to be a selective inhibitor of JAK1/3 signaling as described³⁴. Cells were cultured in a CO₂ incubator at 37°C and medium with cytokines and inhibitors were changed every day for a further 4 days of culture. For flow cytometry analyses, cells were restimulated with 1 µg/mL SIINFEKL in medium containing 2 µM monensin (Calbiochem, San Diego, CA) for 4 hrs. For ELISA, cells were restimulated with 1 µg/mL SIINFEKL in medium for 4 hrs at a concentration of 1x10⁶ cells/mL.

Steroid-induced apoptosis and effects on cytokine production

To study steroid-induced cell apoptosis, thymocytes were isolated from C57BL/6 mice. Tc1 and Tc2 cells were differentiated from OT1 cells for 4 days. Cells (1x10⁶), differentiated under normoxia or hypoxia, were cultured in the presence of 0, 10, 100, 1000 nM dexamethasone (DEX) (Sigma, St. Louis, MO) dissolved in methanol for 24 hrs. Annexin V-positive cells were detected by eBioscience™ Annexin V Apoptosis Detection Kit APC (Thermo Scientific, Grand Island, NY) and analyzed by flow cytometry.

To study the impact of DEX on cytokine production, Tc2 cells were differentiated under normoxia or hypoxia. Cells (1x10⁶) were incubated with 0, 1, 10, 100nM DEX

dissolved in methanol for 1 hr. Cells were then restimulated with 1 µg/mL SIINFEKL in medium for 4 hrs at a concentration of 1×10^6 cells/mL. Supernatant IL-13 production was measured by ELISA.

RNA preparation and analyses

Total RNA was extracted from 1×10^6 differentiated CD8⁺ T cells using the NucleoSpin RNA II isolation kit (Macherey-Nagel, Düren, Germany) following the manufacturer's protocol. Reverse transcription of total RNA (1 µg) was performed using the QuantiTect reverse transcription kit (Qiagen, Valencia, CA) following the manufacturer's protocol. Quantitative real-time PCR was performed using the SYBR Green RT-PCR Kit and the ABI 7500 fast real-time PCR system (Applied Biosystems, Foster City, CA). Primers for GATA3 were as follows: *Gata3* forward 5'-GACTCTTCCCACCCAGCAGC-3', reverse 5'-CCATCTCGCCGCCACAG-3'. Primers for T-bet were as follows: *Tbx21* forward 5'-CAACCAGCACCCAGACAGAGATG-3', reverse 5'-GACCACATCCACAAACATCCTG-3'. Primers for HIF-1α were as follows: *Hif-1α* forward 5'-AACGACCACTGCTAAGGCAT-3', reverse 5'-GGCTCCTTGGATGAGCTTTG-3'.

The determined cycle threshold (CT) reflects the number of PCR cycles required for the fluorescence signal to exceed the detection threshold, which was set to the log-linear range of the amplification curve. The differences in CT values of the gene of interest and the house keeping gene 18SrRNA were used to calculate delta CT (Δ CT) values. Relative fold changes were then calculated using the $2^{-\Delta\Delta CT}$ algorithm.

Immunoblot analyses

CD8⁺ T cells (5×10^6) were lysed in SDS buffer containing Halt protease and phosphatase inhibitor mixture (Thermo Scientific, Grand Island, NY) and sonicated for 10 seconds. Samples were heated for denaturation at 95°C and analyzed by SDS/PAGE and transferred to nitrocellulose membranes. The membranes were blocked using buffer containing 5% (wt/vol) non-fat milk and 0.5% sodium azide in tris-buffered saline with tween (TBST) for 1 hr and incubated with rabbit anti-HIF-1 α mAb (Clone D2U3T, Cell Signaling, Boston, MA) overnight at 4°C. Horseradish peroxidase-conjugated anti-rabbit IgG (GE Healthcare, Wauwatosa, WI) was used to detect HIF-1 α protein. Mouse monoclonal anti- β -actin antibody (Sigma) was used as an internal control. Immunoreactive bands of Western blots were quantified by densitometric quantification of autoradiographs using ImageJ (National Institutes of Health) and expressed as relative HIF-1 α normalized by β -actin.

CD8⁺ T cell transfection

All retroviral constructs were derived from the MSCV2.2-IRES-GFP retroviral vector (provided by Dr. J. Hagman, National Jewish Health, Denver, CO). Generation of retroviruses and infection of cells were described previously³⁵. Briefly, Phoenix packaging cells were transfected in a 6-well plate with 20 μ g retroviral vector (with GATA3 shRNA or scrambled shRNA) using 10 μ L/well Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Viral supernatants were collected after 24-48 hrs. On day 0, 2-3 mL of viral particles were used to transduce 1×10^6 CD8⁺ T cells. Medium with IL-2+IL-4 was changed every day for an additional 4

days. GFP+ cells were sorted on day 4 using the MoFlo flow cytometer (Beckman Coulter, Fort Collins, CO).

Flow cytometric analyses

Intracellular staining of CD8+ T cells was carried out following stimulation SIINFEKL as described above. Cells were incubated with anti-mouse CD16/CD32 (2.4G2; BD Bioscience, San Jose, CA) at 4°C for 5 minutes. After fixation with fixation buffer (BD Biosciences) and permeabilization with 0.1% saponin (Sigma), cells were then stained with APC-labeled anti-mouse IFN γ (XMG 1.2; eBioscience, San Diego, CA) and PE-labeled anti-mouse IL-13 (eBio13A; eBioscience). For staining of phosphorylated STAT6 and GATA3, CD8+ T cells differentiated in IL-2 + IL-4 for 1, 4, 24 hrs without SIINFEKL stimulation. Cells were stained with APC-labeled anti-mouse CD8 α (53-6.7; eBioscience) and FITC-labeled anti-mouse CD3(17A2; eBioscience) then stained with PE-labeled anti-human/mouse GATA3 (TWAJ; eBioscience) or cells were stained with FITC-labeled anti-mouse CD8 α (53-6.7; eBioscience) and PE-labeled anti-mouse CD3 (17A2; BD Biosciences) then stained with Alexa Fluor 647-labeled anti-mouse STAT6 (pY641; BD Biosciences). Cell staining was analyzed using the Flowjo software (Tree Star, Ashland, OR).

Secondary allergen challenge model and adoptive transfer

The secondary challenge model was used as previously described³⁶ to reduce the time between cell manipulation, transfer, and assay. The experimental protocol for sensitization and challenge to OVA was as described previously^{16, 36}, with some

modifications. CD8-deficient mice were sensitized with 20 µg of OVA (Calbiochem, Calbiochem, La Jolla, CA) emulsified in 1.0 mg of alum (AlumImject; Pierce, Rockford, IL) on days 0 and 14 by intraperitoneal injection. Mice were challenged (primary) with 0.2% OVA for 20 minutes on days 21, 22, and 23 using an ultrasonic nebulizer (model NE-U07; Omron Healthcare, Kyoto, Japan). CD8⁺ T cells (8×10^5) generated in medium containing IL-2+IL-4 under 21% O₂ or 3% O₂ were injected intravenously into OVA-sensitized CD8-deficient mice on day 37. Two hrs after transfer, mice were challenged (secondary) with 1% OVA for 20 minutes. Airway function was measured and samples were collected on day 39. Airway function was assessed as described previously³⁷. Briefly, changes in airway resistance (RL) of anesthetized and intubated mice were measured using a whole body plethysmography-based system with artificial ventilation in response to increasing doses of inhaled methacholine (Sigma). Data are presented as percent change from the baseline RL values after saline inhalation. Baseline RL values were not significantly different among the various groups.

BAL analyses

After measurement of airway function, lungs were lavaged via the tracheal tube with 1 mL of HBSS. The supernatants were collected, and IFN γ , IL-4, IL-5, and IL-13 (eBioscience) levels were measured by ELISA and total leukocyte numbers were counted and differentiated as described previously^{16, 31}.

Lung histology

Lungs were fixed in 10% formalin, and then embedded in paraffin^{16, 17, 31-33, 38}. Paraffin sections (5- μ m thick) were stained with PAS. Mucus-containing goblet cells were quantified. Histology analyses was performed in a blinded manner under light microscopy linked to an image system. The numbers of PAS-positive goblet cells were determined in cross-sectional areas of the airway wall. Six to ten different sections were evaluated per animal. The measurements were averaged for each animal and the mean values ($\pm$ SEM) were determined for each group.

Statistical analysis

Data from *in vivo* experiments were from at least three independent experiments with four mice per group or where the number of replicates is indicated. Results were expressed as means $\pm$ SEM. Student's two-tailed t test was used to determine the levels of difference between the two groups. ANOVA was used to determine the levels of difference among more than three groups. Nonparametric analysis using the Mann-Whitney U test or Kruskal-Wallis test was also used to confirm that the statistical differences remained significant even if the underlying distribution was uncertain. The P values for significance were set to 0.05 for all tests.

Results

Hypoxia enhances IL-4-dependent CD8⁺ T cell transcriptional reprogramming

To determine the effects of hypoxia on CD8⁺ T cell differentiation, splenic OT-1 CD8⁺ T cells were differentiated *in vitro* for four days in the presence of IL-2 or IL-2+IL-4 under normoxic (21% O₂) or hypoxic (3% O₂) conditions. As previously shown¹⁷, in the presence of IL-2, CD8⁺ T cells were predominantly IFN γ -producers (Tc1). In the presence of IL-2 and IL-4, a marked increase in IL-13⁺ T cells (Tc2) was observed when cultured under normoxic conditions (Figs. 1A-1C). Following differentiation, CD8⁺ Tc1 and Tc2 cells remained resistant to DEX-induced apoptosis, unlike, for example, thymocytes (Fig. S1A). When cells were differentiated under hypoxia, the effect on Tc1 cells was minimal. In contrast, when Tc2 cells were differentiated under hypoxia, the number of IL-13⁺ cells was markedly increased and IFN γ ⁺ cell numbers were correspondingly decreased. Following *in vitro* culture of these cells in the presence of IL-2+IL-4 (4 days) and antigen activation (4 hrs), the levels of IL-13 released from cells cultured under hypoxia were more than double compared to cells cultured under normoxic conditions (Fig. 1D). As shown in Figure 1, the effects of hypoxia exposure were only seen in the presence of IL-4 and were restricted to Tc2 and not Tc1 differentiation. When CD4⁺ T cells were differentiated under Th2 polarizing conditions, hypoxia conditioning did not enhance IL-13 production (data not shown). There was little difference between cells differentiated in 3% or 1% oxygen when numbers of IL-13⁺ cells or IL-13 production were examined (data not shown). As cell viability was lower under 1% oxygen conditioning, all further hypoxia experiments were carried out under 3% oxygen. When cytokine production was monitored following addition of DEX,

hypoxia-treated CD8⁺ T cells were less affected than the normoxia-exposed group. Even at the highest dose of DEX, cytokine production was largely maintained (Fig. S1B).

Enhancement of allergen-induced airway responses following adoptive transfer of hypoxia-exposed Tc2 cells

Adoptive transfer of Tc2 cells prior to challenge of sensitized CD8-deficient recipients resulted in the full restoration of AHR, mucus hyperproduction, and airway eosinophilia¹⁷. Since hypoxia enhanced Tc2 differentiation *in vitro*, we compared *in vivo* outcomes after adoptive transfer of Tc2 cells exposed to either normoxia or hypoxia into OVA-sensitized or non-sensitized CD8-deficient mice prior to secondary allergen challenge. OVA-sensitized recipients of Tc2 cells differentiated under normoxia developed airway allergic responses including methacholine-induced AHR and airway eosinophilia (Figs. 2A and 2B). OVA-sensitized recipients of Tc2 cells differentiated under hypoxia showed significantly increased AHR and airway eosinophilia compared to OVA-sensitized recipients of Tc2 cells differentiated under normoxia. Non-sensitized recipients of Tc2 cells differentiated under normoxia did not develop allergic airway responses.

Lung tissue sections were processed for histological analyses and areas stained with PAS were measured. As shown in Figures 2C and 2D, OVA-sensitized recipients of Tc2 cells differentiated under hypoxia showed marked increases in inflammatory cell accumulation and significantly increased numbers of mucus-producing goblet cells compared to OVA-sensitized recipients of Tc2 cells differentiated under normoxia.

When bronchoalveolar lavage (BAL) fluid was assayed at 48 hrs for cytokine levels (the time AHR and airway inflammation peaked) levels of IFN γ , IL-4, IL-5, and IL-13 were similar in both sensitized recipient groups (Fig. S2). This was not surprising, as in the secondary challenge model, cytokine levels between groups were most different at 6 hrs after the last challenge³⁶.

Hypoxia exposure leads to increased HIF-1 α , pSTAT6, and GATA3 protein levels in Tc2 cells

Hypoxia inducible factors are transcription factors that facilitate cellular responses to hypoxia and play different roles depending on the specific T-cell subset examined^{23, 39}. To determine the molecular events that accompanied IL-4-dependent Tc2 differentiation under normoxia or hypoxia, mRNA expression levels of *Hif-1 α* , *Tbx21*, and *Gata3* were examined. When differentiated in IL-2+IL-4, increases in *Hif-1 α* and *Gata3* and decreases in *Tbx21* mRNA were detected, but no significant differences in expression levels of these genes were detectable in cells differentiated under normoxia or hypoxia for 96 hrs (Fig. S3). However, as shown in Figure 3, HIF-1 α , phosphorylated signal transducer and activator of transcription 6 (pSTAT6) and GATA3 protein levels were significantly increased at 24 hrs following hypoxia exposure in Tc2 cells compared to cultures carried out under normoxia. pSTAT6 protein levels measured as early as 1 hr and 4 hrs following hypoxia exposure were not increased and increases were first detected at 24 hrs following hypoxia exposure (Fig. S4). These data indicated that hypoxia-enhanced Tc2 differentiation was associated with the upregulation of HIF-1 α , pSTAT6, and GATA3 protein levels at an early time-point during differentiation.

Following binding of IL-4 to the IL-4 receptor, Janus kinase 1 (JAK1) and Janus kinase 3 (JAK3) were activated, leading to the activation and phosphorylation of STAT6 in CD8⁺ T cells⁴⁰. To determine the events leading to IL-4-dependent regulation of HIF-1 α , we added an inhibitor of JAK1 and JAK3 during CD8⁺ T-cell differentiation. We previously showed this inhibitor to be selective for Th2 and not Th1 or Th17 cells. When administered to allergen sensitized and challenged mice, inhibition significantly reduced the full spectrum of lung allergic responses³⁴. As shown in Figure S5A, Tc2 differentiation as determined by numbers of IL-13⁺CD8⁺ T cells was reduced in the presence of the inhibitor in a dose-dependent manner. In parallel, *Hif-1 α* mRNA expression was significantly reduced with increasing concentrations of the inhibitor (Fig. S5B).

As previously demonstrated, *GATA3* was induced by IL-4 during CD8⁺ Tc2 differentiation¹⁷. To determine whether *GATA3* regulates *Hif-1 α* gene expression during Tc2 differentiation, CD8⁺ T cells differentiated in the presence of IL-2 and IL-4 under normoxia were transfected with a green fluorescent protein (GFP)-encoding virus containing an shRNA construct specific for mouse *GATA3*. A noneffective 29-mer scrambled shRNA was used as a control. Four days after virus infection and differentiation in the presence of IL-2+IL-4, GFP-positive cells were sorted and Tc2 differentiation and *Hif-1 α* mRNA expression were assessed. Among the GFP-positive cells, the numbers of IL-13⁺ cells identified following antigen-restimulation were significantly lower in cells transfected with *GATA3* shRNA in comparison to the scrambled shRNA (Fig. S5C). In parallel, *Hif-1 α* gene expression was significantly lower in the *GATA3* shRNA transfected, GFP-positive cells (Fig. S5D). Taken together, these

data suggested that in CD8⁺ T cells, *Hif-1 α* gene expression was upregulated by IL-4 through JAK1/3 and *GATA3* activation.

Inhibition of HIF-1 α impairs Tc2 differentiation under both normoxia and hypoxia

HIFs form a heterodimeric complex which acts as a transcriptional regulator of genes whose promoters contain hypoxia response elements (HREs)²³. This complex is comprised of HIF-1 β , which is constitutively expressed, and either of the HIF-1 α isoforms, HIF-1 α or HIF-2 α ²³. To determine the role of HIF-1 α or HIF-2 α in CD8⁺ Tc2 differentiation, we examined the influence of two HIF inhibitors, BAY 87-2243 and HIF-C2. BAY 87-2243 targets mitochondrial complex 1 and is suggested to inhibit HIF-1 α ⁴¹. HIF-C2 is a potent and selective allosteric inhibitor of HIF-2 α binding within the internal cavity of HIF-2 α , disrupting hetero-dimerization of the full-length HIF-2 transcription factor^{42, 43}. As shown in Figure 4A, BAY 87-2243 impaired Tc2 differentiation under normoxic and hypoxic conditioning. When culture supernatants from TCR-stimulated Tc2 cells were compared, IL-13 secretion was also markedly reduced by BAY 87-2243 (Fig. 4B). In contrast, the inhibition of HIF-2 α by HIF-C2 *in vitro* did not affect Tc2 differentiation under either normoxic or hypoxic conditioning (Fig. 4B). These results suggested that HIF-1 α but not HIF-2 α played a critical role in IL-4-dependent Tc2 differentiation and the enhancement seen under hypoxic conditioning.

Consequences of HIF-1 α deficiency in Tc2 differentiation under hypoxic conditioning

To directly determine the role of HIF-1 α in the IL-4-dependent transcriptional reprogramming of CD8⁺ T cells, CD8⁺ T cells were harvested from progeny derived from crossing Lck-Cre/HIF-1 α^{flox} mice in which T cells from OT-1 mice were rendered deficient in HIF-1 α (HIF knock-out (KO)). Cells from Lck-Cre mice crossed with OT-1 mice served as (wild type, WT) controls. Cells were differentiated in the presence of IL-2 or IL-2+IL-4 under normoxia or hypoxia. As shown in Figure S6, HIF KO CD8⁺ T cells were not completely deficient in HIF-1 α ; levels were reduced by approximately 85% in T lymphocytes including CD8⁺ T cells isolated from HIF KO mice. HIF KO CD8⁺ T cells, similar to the WT controls, were fully capable of Tc1 differentiation in the presence of IL-2 when differentiated under normoxia or hypoxia (Fig. S7), further confirming the selectivity of the effects of hypoxia on Tc2 conversion and the normalcy of responses to IL-2 (Tc1) in the genetically-manipulated HIF KO mice. Under normoxia, Tc2 differentiation was not significantly altered in CD8⁺ T cells from HIF KO mice compared to cells from the WT controls. However, the frequency of IL-13 single-positive cells was significantly lower in HIF KO compared to WT CD8⁺ T cells differentiated under hypoxia (Fig. 5A). In parallel, analyses of secreted protein levels in cell culture supernatants confirmed significantly decreased IL-13 production from HIF KO Tc2 cells compared to WT Tc2 cells cultured under hypoxia (Fig. 5B). HIF-1 α deficiency did not significantly alter IL-13 secretion when the cells were differentiated under normoxia. These data confirmed that the increased Tc2 differentiation seen under hypoxic conditioning was dependent on HIF-1 α .

Impaired development of allergen-induced airway responses following adoptive transfer of hypoxia-exposed HIF-1 α -deficient Tc2 cells

Since hypoxia enhanced both Tc2 differentiation *in vitro* and allergic airway responses after adoptive transfer of Tc2 cells exposed to hypoxia into sensitized CD8-deficient mice prior to secondary allergen challenge, we compared the outcomes of transfer of WT and HIF-1 α -deficient Tc2 cells differentiated under hypoxia. Recipients of WT Tc2 cells differentiated under hypoxia developed significant airway allergic responses including methacholine-induced AHR and airway eosinophilia (Figs. 6A and 6B) compared to mice that did not receive any cells. Recipients of HIF-1 α -deficient Tc2 cells differentiated under hypoxia showed significantly reduced enhancement of AHR and airway eosinophilia compared to the recipients of WT Tc2 cells differentiated under hypoxia (Figs. 6A and 6B).

Lung tissue sections were processed for analyses of histological changes and PAS+ cells. As shown in Figures 6C and 6D, recipients of HIF-1 α -deficient Tc2 cells differentiated under hypoxia showed marked decreases in inflammatory cell accumulation and significantly decreased numbers of mucus-producing goblet cells compared to recipients of WT Tc2 cells differentiated under hypoxia.

Discussion

Despite the findings that increased hypoxia-related responses have been demonstrated in asthma, the specific pathways activated or mechanistic consequences have not been well defined, especially in the context of disease pathobiology. The goals of this study were to delineate the role of hypoxia-related responses in mice specifically as they pertained to CD8⁺ Tc2-mediated experimental asthma. We demonstrated that CD8⁺ T-cell differentiation to IL-13-producing Tc2 cells was enhanced by hypoxia exposure with significantly increased numbers of IL-13-producing cells and, following culture, significantly increased IL-13 production. These effects were specific to Tc2 cells in the presence of IL-4 and were not detected in Tc1 cells or CD4⁺ Th2 cells. In Tc2 cells differentiated under hypoxia, increased levels of HIF-1 α , pSTAT6, and GATA3 protein were detected. Sensitized and challenged CD8-deficient mice which received Tc2 cells differentiated under hypoxia prior to secondary challenge developed enhanced airway reactivity to inhaled methacholine and eosinophilic airway inflammation compared to recipients of Tc2 cells differentiated under normoxia.

Hypoxia inducible factors serve as decisive transcription factors of a variety of biological responses²³. HIFs are heterodimeric proteins containing one α subunit and one β subunit. While the β subunit is constitutively expressed, the α subunits are degraded by von Hippel Lindau complex but are stabilized under hypoxia²³. Previous studies have demonstrated that HIF-1 α may exhibit different activities in asthma⁴⁴⁻⁴⁶. The nonspecific HIF inhibitor 2-methoxyestradiol (2ME) reduced pulmonary inflammatory and airway remodeling responses to ovalbumin (OVA) in mice⁴⁵. In mice heterozygous for a HIF-1 α null allele, diminished lung eosinophilia in response to OVA

challenge was demonstrated⁴⁷. Following exposure of mice to a hypoxic environment (10% O₂) during allergen challenge, the contributions of hypoxia to airway inflammation and remodeling were determined⁴⁸. Although neither hypoxia nor OVA alone induced significant neutrophil influx into the lung, the combination of OVA and hypoxia induced a synergistic increase in peribronchial neutrophils and enhanced expression of HIF-1 α and the CXC-family neutrophil chemokine KC. In addition, the combination of hypoxia and OVA increased eotaxin-1, peribronchial eosinophilia, lung TGF- β 1 expression, and indices of airway remodeling (fibrosis and smooth muscle) compared to either stimulus alone.

To define the role of the α subunits of HIFs in the hypoxia-induced enhancement of CD8⁺ Tc2 cell differentiation, HIF-1 α and HIF-2 α inhibitors were utilized. Although there is some controversy as to the specificity of these inhibitors⁴¹⁻⁴³, our data suggested that HIF-1 α but not HIF-2 α was essential to the enhancement of Tc2 differentiation under hypoxic conditioning. When the two inhibitors were compared, HIF-C2 a selective allosteric inhibitor of HIF-2 α was shown to have no effect on Tc2 conversion in cells exposed to normoxia or hypoxia; HIF-1 α inhibitor, BAY 87-2243 led to decreases in IL-13⁺ Tc2 cells and IL-13 production from cultured Tc2 cells. In contrast to Tc2 differentiation, Tc1 differentiation was not affected by either drug.

To confirm the importance of HIF-1 α in Tc2 differentiation in the response to hypoxia, HIF-1 α -deficient mice were used where HIF-1 α expression was depleted exclusively in T cells. Although not completely deficient in HIF-1 α protein (approximate 85% reduction), the results using differentiated CD8⁺ T cells from these mice established several important aspects. HIF-1 α -deficient CD8⁺ T cells were fully capable

of Tc1 differentiation in the presence of IL-2 alone. The effects of the deficiency of HIF-1 α were most obvious in Tc2 cells exposed to hypoxia where the frequency of IL-13+CD8+ T cells was lower and IL-13 production was markedly reduced compared to similarly treated WT CD8+ T cells. In the model of experimental asthma, we previously showed that transferred CD8+ T cells which were exposed to an environment rich in IL-4 displayed changes at the GATA3 and IL-13 promoter indicative of transcriptional activation and increased IL-13 production¹⁷. Transfer of these cells into CD8-deficient mice fully restored all lung allergic responses¹⁷. Transfer of hypoxia-exposed, HIF-1 α -deficient CD8+ T cells into CD8-deficient recipients failed to restore the full spectrum of lung allergic responses as seen following transfer of hypoxia-exposed WT CD8+ T cells. Taken together, the findings established that enhanced Tc2 differentiation under hypoxia was mediated through HIF-1 α activation.

In this study, we demonstrated that when CD8+ T cells were differentiated under normoxia, *HIF-1 α* mRNA was increased by IL-4 and that hypoxia exposure further enhanced HIF-1 α protein expression in Tc2 cells. As well, increased levels of pSTAT6 and GATA3 protein were only detected in cells differentiated under hypoxia in the presence of IL-2 and IL-4, but not with IL-2 alone. IL-4 exerts the majority of its activity by signaling through STAT6. In response to IL-4 binding to its receptor, JAK1 and JAK3 are phosphorylated which in turn phosphorylates STAT6⁴⁰. STAT6 is then dimerized and transported to the nucleus where it regulates gene expression. In activated CD8+ T cells, IL-13 induction progressed through a series of distinct IL-4/GATA3-regulated stages characterized by gene expression and epigenetic changes¹⁷. *In vitro*, IL-4 triggered the stepwise molecular conversion of CD8+ T cells from IFN γ to IL-13

production. During the initial stage, IL-4 suppressed T-bet expression and induced GATA3 expression, characterized by histone modifications and RNA polymerase II (Pol II) recruitment to the GATA3 locus. Exposure to hypoxia appears to have enhanced these molecular events including increases in levels of pSTAT6 and GATA3. Both inhibition of JAK1/3 activation, leading to reduced pSTAT6, and silencing of GATA3 reduced Tc2 differentiation and *Hif-1 α* gene expression suggesting that HIF-1 α is regulated by IL-4 downstream of JAK1/3 and GATA3 activation. It is unclear at present at what level hypoxia and HIF-1 α enhanced this IL-4-JAK1/3-pSTAT6-GATA3-IL-13 cascade.

The IL-4-dependent upregulation of HIF-1 α in CD8⁺ T cells is in contrast to reports in other cell types. In fibroblast-like synoviocytes, IL-4 did not alter levels of HIF-1 α ⁴⁹; in macrophages, IL-4 reduced HIF-1 α translation⁵⁰. Thus, effects of IL-4 on HIF-1 α activation appear variable and dependent on the cell type. To date, only limited numbers of studies have investigated the specific influence of hypoxic conditioning on CD8⁺ T cells. The mammalian target of rapamycin complex 1 (mTORC1) is suggested to be involved in the regulation of HIF-1 α in effector CD8⁺ T cells⁵¹. Silly *et al.* explored the impact of hypoxia on effector CD8⁺ T cells cultured under 5% or 1% O₂^{52, 53}. These studies revealed that oxygen deprivation did not modify CD8⁺ cytotoxic T lymphocyte (CTL) killing capacities but potently induced IL-10 secretion upon reactivation and dramatically decreased CTL expansion. Of note, 5% O₂ was defined as “physioxia” reflecting the general levels of oxygen fraction in healthy tissues and 1% O₂ as “hypoxia”, levels found in inflamed or tumor sites⁵³. In the present study, we observed similar effects on IL-13 production following Tc2 differentiation whether cells were

differentiated in 3% or 1% O₂.

A critical question in all of the studies associating hypoxia with asthma, experimental or in asthmatics, is where hypoxic conditioning of cells occurs and at what levels of O₂ concentration. Standard cell culture conditions (95% air and 5% CO₂) expose cells to 20% O₂ which is much higher than the O₂ concentrations to which most immune cells are exposed to *in vivo*. Physioxia in different tissues varies greatly; in the skin (1.1%), in the brain (4.4%), and was as high as 14.5% in pulmonary alveoli⁵³. Tissue oxygen concentrations are likely even lower during an inflammatory response as edema interferes with the diffusion of oxygen from the microvasculature and the infiltration of inflammatory cells results in increased O₂ consumption⁵³. The concentration of oxygen in secondary lymphoid organs is generally low⁵⁴, suggesting that HIFs may be activated in lymphocytes during their normal circulation in the body. More research is needed to better understand potential effects of varying oxygen concentrations on the differentiation and survival of subsets of T lymphocytes in various target organs. Activation of the hypoxia response pathway and increases in HIF-1 α can be induced without hypoxic conditioning as seen in response to inflammation. Moreover, HIF-1 α activity can be associated with asthma directly⁴⁴⁻⁴⁷.

In summary, hypoxia conditioning significantly enhanced IL-4-dependent reprogramming of CD8⁺ T cells to IL-13 production through activation of HIF-1 α . Activation of HIF-1 α , STAT6, and GATA3 may be relevant not only to severe asthma, but also be present in mild and moderate asthmatics. The Tc2 cells differentiated under hypoxia were capable of enhancing allergen-induced airway inflammation and AHR. Together with the insensitivity of CD8⁺ T cells to corticosteroids¹⁶, activation of the IL-

560 4-hypoxia-HIF-1 α -IL-13 axis may play a role in the development of severe, steroid-
561 refractory asthma.

562

563

Acknowledgments

The authors are grateful to Dr. Holger Eltzschig for providing the HIF-1 α -deficient mice and to Diana Nabighian and Cynthia Chavez for assistance in preparation of the manuscript.

References

1. Bel EH, Sousa A, Fleming L, Bush A, Chung KF, Versnel J, et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). *Thorax* 2011; 66:910-7.
2. Bush A, Zar HJ. WHO universal definition of severe asthma. *Curr Opin Allergy Clin Immunol*; 11:115-21.
3. Brusselle G, Bracke K. Targeting immune pathways for therapy in asthma and chronic obstructive pulmonary disease. *Ann Am Thorac Soc* 2014; 11:S322-8.
4. Hansbro PM, Kim RY, Starkey MR, Donovan C, Dua K, Mayall JR, et al. Mechanisms and treatments for severe, steroid-resistant allergic airway disease and asthma. *Immunol Rev* 2017; 278:41-62.
5. Martin AA, Fainardi V, Saglani S. Severe therapy resistant asthma in children: translational approaches to uncover sub-phenotypes. *Expert Rev Respir Med* 2017; 11:867-74.
6. Bhakta NR, Erle DJ. IL-17 and "TH2-high" asthma: Adding fuel to the fire? *J Allergy Clin Immunol* 2014; 134:1187-8.
7. Alcorn JF, Crowe CR, Kolls JK. TH17 Cells in Asthma and COPD. *Annual Review of Physiology* 2010; 72:495-516.
8. Wang M, Gao P, Wu X, Chen Y, Feng Y, Yang Q, et al. Impaired anti-inflammatory action of glucocorticoid in neutrophil from patients with steroid-resistant asthma. *Respir Res.* 2016; 17:153.

- 594 9. Saffar AS, Ashdown H, Gounni AS. The Molecular Mechanisms of
 595 Glucocorticoids-Mediated Neutrophil Survival. *Current Drug Targets* 2011;
 596 12:556-62.
- 597 10. McKinley L, Alcorn JF, Peterson A, DuPont RB, Kapadia S, Logar A, et al. TH17
 598 Cells Mediate Steroid-Resistant Airway Inflammation and Airway
 599 Hyperresponsiveness in Mice. *The Journal of Immunology* 2008; 181:4089-97.
- 600 11. Kim HY, Umetsu DT, Dekruyff RH. Innate lymphoid cells in asthma: Will they
 601 take your breath away? *Eur J Immunol* 2016; 46:795-806.
- 602 12. Belvisi MG. Regulation of inflammatory cell function by corticosteroids. *Proc Am*
 603 *Thorac Soc* 2004; 1:207-14.
- 604 13. Hilvering B, Hinks TSC, Stöger L, Marchi E, Salimi M, Shrimanker R, et al.
 605 Synergistic activation of pro-inflammatory type-2 CD8⁺ T lymphocytes by lipid
 606 mediators in severe eosinophilic asthma. *Mucosal Immunol*. 2018.
- 607 14. den Otter I, Willems LN, van Schadewijk A, van Wijngaarden S, Janssen K, de
 608 Jeu RC, et al. Lung function decline in asthma patients with elevated bronchial
 609 CD8, CD4 and CD3 cells. *Eur Respir J*, 2016:393-402.
- 610 15. Oda H, Kawayama T, Imaoka H, Sakazaki Y, Kaku Y, Okamoto M, et al.
 611 Interleukin-18 expression, CD8(+) T cells, and eosinophils in lungs of
 612 nonsmokers with fatal asthma. *Ann Allergy Asthma Immunol* 2014; 112:23-8 e1.
- 613 16. Ohnishi H, Miyahara N, Dakhama A, Takeda K, Mathis S, Haribabu B, et al.
 614 Corticosteroids enhance CD8⁺ T cell-mediated airway hyperresponsiveness and
 615 allergic inflammation by upregulating leukotriene B4 receptor 1. *J Allergy Clin*
 616 *Immunol* 2008; 121:864-71 e4.

17. Jia Y, Takeda K, Han J, Joetham A, Marcus RA, Lucas JJ, et al. Stepwise epigenetic and phenotypic alterations poise CD8⁺ T cells to mediate airway hyperresponsiveness and inflammation. *J Immunol* 2013; 190:4056-65.
18. van Rensen EL, Sont JK, Evertse CE, Willems LN, Mauad T, Hiemstra PS, et al. Bronchial CD8 cell infiltrate and lung function decline in asthma. *Am J Respir Crit Care Med* 2005; 172:837-41.
19. Lloyd CM, Hessel EM. Functions of T cells in asthma: more than just T(H)2 cells. *Nat Rev Immunol* 2010; 10:838-48.
20. Dakham A, Collins ML, Ohnishi H, Goleva E, Leung DY, Alam R, et al. IL-13-producing BLT1-positive CD8 cells are increased in asthma and are associated with airway obstruction. *Allergy* 2013; 68:666-73.
21. Cho SH, Stanciu LA, Holgate ST, Johnston SL. Increased interleukin-4, interleukin-5, and interferon-gamma in airway CD4⁺ and CD8⁺ T cells in atopic asthma. *Am J Respir Crit Care Med* 2005; 171:224-30.
22. Cagnoni EF, Ferreira DS, Ferraz da Silva LF, Nicoletti Carvalho Petry AL, Gomes dos Santos AB, Rodrigues Medeiros MC, et al. Bronchopulmonary lymph nodes and large airway cell trafficking in patients with fatal asthma. *J Allergy Clin Immunol* 2015; 135:1352-7 e1-9.
23. Palazon A, Goldrath AW, Nizet V, Johnson RS. HIF transcription factors, inflammation, and immunity. *Immunity* 2014; 41:518-28.
24. Fajardo I, Svensson L, Bucht A, Pejler G. Increased levels of hypoxia-sensitive proteins in allergic airway inflammation. *Am J Respir Crit Care Med* 2004; 170:477-84.

25. Crotty Alexander LE, Akong-Moore K, Feldstein S, Johansson P, Nguyen A, McEachern EK, et al. Myeloid cell HIF-1 α regulates asthma airway resistance and eosinophil function. *J Mol Med (Berl)* 2013; 91:637-44.
26. Dang EV, Barbi J, Yang HY, Jinasena D, Yu H, Zheng Y, et al. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. *Cell* 2011; 146:772-84.
27. Kumar V, Gabrilovich DI. Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment. *Immunology* 2014; 143:512-9.
28. Doedens AL, Phan AT, Stradner MH, Fujimoto JK, Nguyen JV, Yang E, et al. Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen. *Nat Immunol* 2013; 14:1173-82.
29. Nakamura H, Makino Y, Okamoto K, Poellinger L, Ohnuma K, Morimoto C, et al. TCR Engagement Increases Hypoxia-Inducible Factor-1 Protein Synthesis via Rapamycin-Sensitive Pathway under Hypoxic Conditions in Human Peripheral T Cells. *The Journal of Immunology* 2005; 174:7592-9.
30. Clambey ET, McNamee EN, Westrich JA, Glover LE, Campbell EL, Jedlicka P, et al. Hypoxia-inducible factor-1 α -dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. *Proc Natl Acad Sci U S A* 2012; 109:10.
31. Miyahara N, Swanson BJ, Takeda K, Taube C, Miyahara S, Kodama T, et al. Effector CD8⁺ T cells mediate inflammation and airway hyper-responsiveness. *Nat Med* 2004; 10:865-9.
32. Miyahara N, Takeda K, Kodama T, Joetham A, Taube C, Park JW, et al. Contribution of Antigen-Primed CD8⁺ T Cells to the Development of Airway

- Hyperresponsiveness and Inflammation Is Associated with IL-13. *The Journal of Immunology* 2004; 172:2549-58.
33. Miyahara N, Takeda K, Miyahara S, Taube C, Joetham A, Koya T, et al. Leukotriene B4 Receptor-1 Is Essential for Allergen-Mediated Recruitment of CD8+ T Cells and Airway Hyperresponsiveness. *The Journal of Immunology* 2005; 174:4979-84.
34. Ashino S, Takeda K, Li H, Taylor V, Joetham A, Pine PR, et al. Janus kinase 1/3 signaling pathways are key initiators of TH2 differentiation and lung allergic responses. *J Allergy Clin Immunol* 2014; 133:1162-74.
35. Maier H, Colbert JF, D., Clark D, Hagman J. Activation of the early B-cell-specific mb-1 (Ig-alpha) gene by Pax-5 is dependent on an unmethylated Ets binding site. *Mol Cell Biol.* 2003; 23:1946-60.
36. Kanehiro A, Ikemura T, Makela M, Lahn M, Joetham A, Dakhama A, et al. Inhibition of Phosphodiesterase 4 Attenuates Airway Hyperresponsiveness and Airway Inflammation in a Model of Secondary Allergen Challenge. *Am J Respir Crit Care Med* 2001; 163:173-84.
37. Takeda K, Haczku A, Lee JJ, Irvin CG, Gelfand EW. Strain dependence of airway hyperresponsiveness reflects differences in eosinophil localization in the lung. *Am J Physiol Lung Cell Mol Physiol* 2001; 281:L394-L402.
38. Tomkinson A, Cieslewicz G, Duez C, Larson KA, Lee JJ, Gelfand EW. Temporal Association between Airway Hyperresponsiveness and Airway Eosinophilia in Ovalbumin-Sensitized Mice. *Am J Respir Crit Care Med* 2001; 163:721-30.

39. Pollizzi KN, Powell JD. Integrating canonical and metabolic signalling programmes in the regulation of T cell responses. *Nat Rev Immunol* 2014; 14:435-46.
40. Acacia de Sa Pinheiro A, Morrot A, Chakravarty S, Overstreet M, Bream JH, Irusta PM, et al. IL-4 induces a wide-spectrum intracellular signaling cascade in CD8+ T cells. *J Leukoc Biol* 2007; 81:1102-10.
41. Ellinghaus P, Heisler I, Unterschemmann K, Haerter M, Beck H, Greschat S, et al. BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I. *Cancer Med* 2013; 2:611-24.
42. Rogers JL, Bayeh L, Scheuermann TH, Longgood J, Key J, Naidoo J, et al. Development of inhibitors of the PAS-B domain of the HIF-2alpha transcription factor. *J Med Chem* 2013; 56:1739-47.
43. Scheuermann TH, Li Q, Ma HW, Key J, Zhang L, Chen R, et al. Allosteric inhibition of hypoxia inducible factor-2 with small molecules. *Nat Chem Biol* 2013; 9:271-6.
44. Ahmad T, Kumar M, Mabalirajan U, Pattnaik B, Aggarwal S, Singh R, et al. Hypoxia response in asthma: differential modulation on inflammation and epithelial injury. *Am J Respir Cell Mol Biol* 2012; 47:1-10.
45. Huerta-Yepez S, Baay-Guzman GJ, Garcia-Zepeda R, Hernandez-Pando R, Vega MI, Gonzalez-Bonilla C, et al. 2-Methoxyestradiol (2-ME) reduces the airway inflammation and remodeling in an experimental mouse model. *Clin Immunol* 2008; 129:313-24.

46. Kim SR, Lee KS, Lee KB, Lee YC. Recombinant IGFBP-3 inhibits allergic lung inflammation, VEGF production, and vascular leak in a mouse model of asthma. *Allergy* 2012; 67:869-77.
47. Guo J, Lu W, Shimoda LA, Semenza GL, Georas SN. Enhanced interferon-gamma gene expression in T Cells and reduced ovalbumin-dependent lung eosinophilia in hypoxia-inducible factor-1-alpha-deficient mice. *Int Arch Allergy Immunol* 2009; 149:98-102.
48. Baek KJ, Cho JY, Rosenthal P, Alexander LE, Nizet V, Broide DH. Hypoxia potentiates allergen induction of HIF-1alpha, chemokines, airway inflammation, TGF-beta1, and airway remodeling in a mouse model. *Clin Immunol* 2013; 147:27-37.
49. Larsen H, Muz B, Khong TL, Feldmann M, Paleolog EM. Differential effects of Th1 versus Th2 cytokines in combination with hypoxia on HIFs and angiogenesis in RA. *Arthritis Research & Therapy* 2012; 14:R180.
50. Dehne N, Tausendschon M, Essler S, Geis T, Schmid T, Brune B. IL-4 reduces the proangiogenic capacity of macrophages by down-regulating HIF-1alpha translation. *J Leukoc Biol* 2014; 95:129-37.
51. Finlay DK, Rosenzweig E, Sinclair LV, Feijoo-Carnero C, Hukelmann JL, Rolf J, et al. PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells. *J Exp Med* 2012; 209:2441-53.
52. Vuillefroy de Silly R, Ducimetiere L, Yacoub Maroun C, Dietrich PY, Derouazi M, Walker PR. Phenotypic switch of CD8(+) T cells reactivated under hypoxia

toward IL-10 secreting, poorly proliferative effector cells. Eur J Immunol 2015;
45:2263-75.

53. Vuillefroy de Silly R, Dietrich PY, Walker PR. Hypoxia and antitumor CD8+ T
cells: An incompatible alliance? Oncoimmunology 2016; 5:e1232236.

54. Cho SH, Raybuck AL, Stengel K, Wei M, Beck TC, Volanakis E, et al. Germinal
centre hypoxia and regulation of antibody qualities by a hypoxia response
system. Nature 2016; 537:234-8.

Figure Legends

Figure 1: Th1 and Th2 cytokine expression in CD8+ T cells differentiated in IL-2 or IL-2+IL-4 under normoxia or hypoxia.

CD8+ T cells were differentiated *in vitro* for 4 days under normoxia (21% O₂) or hypoxia (3% O₂) in the presence of IL-2 or IL-2+IL-4 followed by SIINFEKL re-stimulation. (A) Representative results (%) of cells staining for IFN γ and IL-13 following SIINFEKL stimulation. (B) Percentages of IL-13 single-positive cells from five independent experiments. (C) Percentages of IFN γ single-positive cells from five independent experiments. (D) Protein levels of IL-13 in 4-day cultures following differentiation in IL-2 or IL-2+IL-4 and activation by SIINFEKL. Results (means $\pm$ SEM) are from 5 independent experiments. ns: not significant, **p<0.01.

Figure 2: Adoptive transfer of hypoxia-exposed CD8+ Tc2 cells into OVA-sensitized CD8-deficient recipients enhances AHR and airway inflammation.

CD8-deficient mice were initially sensitized and challenged and received no cells (OVA/OVA), 4x10⁵ CD8+ T cells differentiated in IL-2+IL-4 under normoxia (OVA/OVA + Tc2_Normoxia) or 4x10⁵ CD8+ T cells differentiated in IL-2+IL-4 under hypoxia (OVA/OVA + Tc2_Hypoxia) prior to secondary challenge. As control, CD8-deficient recipients were not initially sensitized but challenged and received no cells (PBS/OVA) or 4x10⁵ CD8+ T cells differentiated in IL-2+IL-4 under normoxia (PBS/OVA + Tc2_Normoxia) prior to secondary challenge. (A) Changes in R_L were measured in response to increasing concentrations of inhaled MCh. (B) Eosinophil numbers in BAL

fluid. (C) Representative photomicrographs of lung histology (PAS staining): I) PBS/OVA, II) OVA/OVA, III) PBS/OVA + Tc2 normoxia, IV) OVA/OVA + Tc2 normoxia, and V) OVA/OVA + Tc2 hypoxia. (D) Quantitative analysis of goblet cells. Data for A, B, and D (means $\pm$ SEM) are from 2 independent experiments with 8 mice/group. * $p<0.05$ compared to PBS/OVA and OVA/OVA, [†] $p<0.05$ compared to OVA/OVA + Tc2 normoxia.

Figure 3: Lineage-specific transcription factor protein expression in CD8⁺ T cells.

CD8⁺ T cells were differentiated in IL-2 or IL-2+IL-4 under normoxic or hypoxic conditions. (A) HIF-1 α protein levels detected by immunoblot analysis in differentiated CD8⁺ T cells. Representative flow cytometry analyses of (B) pSTAT6 and (C) GATA3 protein expression in Tc2 cells differentiated in IL-2+IL-4 for 24 hrs. Cells were gated on the CD8⁺ population. Solid line, differentiation under normoxia; dashed line, differentiation under hypoxia. Experiments were repeated three times with similar results.

Figure 4: Effect of HIF inhibitors on Tc2 differentiation.

The vehicle (DMSO) or inhibitors BAY 87-2243 (BAY) or HIF-C2 were added during CD8⁺ T cell differentiation. (A) Results of intracellular staining for IL-13 (% positive cells) following SIINFEKL re-stimulation of cells differentiated in IL-2 or IL-2+IL-4 under normoxia or hypoxia. (B) IL-13 protein levels after SIINFEKL re-stimulation of cells differentiated in IL-2 or IL-2+IL-4 under normoxia or hypoxia. Data (means $\pm$ SEM) are from 5 independent experiments. ** $p<0.01$, compared with cells differentiated DMSO or HIF-C2 in each group.

786

787 **Figure 5: IL-13 expression in differentiated HIF-1 α -deficient CD8⁺ T cells.**

788 CD8⁺ T cells from Lck-Cre/OT-1 (WT) and HIF-1 α -deficient Lck-Cre/HIF-1 α^{fllox} /OT-1
 789 (HIF KO) mice were differentiated *in vitro* in the presence of IL-2 or IL-2+IL-4 followed
 790 by SIINFEKL re-stimulation. (A) Results (% positive) of intracellular staining for IL-13 in
 791 cells differentiated in IL-2+IL-4 and SIINFEKL re-stimulation. (B) IL-13 protein levels in
 792 cells differentiated in IL-2 or IL-2+IL-4 under normoxia or hypoxia after SIINFEKL re-
 793 stimulation. Data (means $\pm$ SEM) are from 5 independent experiments. *p<0.05.

794

795 **Figure 6: Adoptive transfer of hypoxia-exposed HIF-1 α -deficient Tc2 cells results**
 796 **in reduced restoration of lung allergic responses in CD8-deficient recipients.**

797 CD8-deficient mice were initially sensitized and challenged and received no cells
 798 (vehicle), 4x10⁵ WT CD8⁺ T cells differentiated in IL-2+IL-4 under hypoxia (WT Tc2) or
 799 4x10⁵ HIF-1 α -deficient CD8⁺ T cells differentiated in IL-2+IL-4 under hypoxia (HIF KO
 800 Tc2) prior to secondary challenge. (A) Changes in R_L were measured in response to
 801 increasing concentrations of inhaled MCh. (B) Eosinophil numbers in BAL fluid. (C)
 802 Representative photomicrographs of lung histology. (D) Quantitative analysis of PAS+
 803 areas. Data (means $\pm$ SEM) are from 2 independent experiments with 8 mice/group.
 804 *p<0.05 compared to vehicle and HIF KO Tc2.

Figure 1 A





Figure 2

A



B





Figure 2

C



D




Figure 3




Figure 4





Figure 5 A



B




Figure 6




Figure 6




Figure S1




Figure S2




Figure S3




Figure S4




Figure S5




Figure S6





Figure S7



**Hypoxia Enhances CD8+ Tc2 Dependent Airway Hyperresponsiveness and
Inflammation Through Hypoxia Inducible Factor 1 α**

Fangkun Ning PhD¹, Katsuyuki Takeda MD, PhD¹, Michaela Schedel PhD¹, Joanne
Domenico BS¹, Anthony Joetham BS¹, Erwin W. Gelfand MD^{1*}

¹Division of Cell Biology, Department of Pediatrics, National Jewish Health,
1400 Jackson Street, Denver, Colorado 80206, USA

Figure Legends

Figure S1: Cell apoptosis and IL-13 expression after dexamethasone treatment.

(A) Thymocytes (Thy), Tc1, and Tc2 cells were incubated with 0, 10, 100, 1000 nM DEX for 24 hrs, Cells were stained for Annexin V. Results are from 3 independent experiments. * $p < 0.05$. (B) Normoxia-treated (21% O₂) and hypoxia-treated (3% O₂) Tc2 cells were incubated in the presence of 0, 1, 10, 100 nM DEX for 1 hr. Cells were then stimulated with SIINFEKL for 4 hrs and supernatant IL-13 was measured by ELISA. Cells without DEX treatment were used as control and IL-13 levels were calculated as a percentage of the controls. Normoxia-treated and hypoxia-treated Tc2 cells were compared at each dose of DEX. Results are from 3 independent experiments. * $p < 0.05$.

Figure S2: Cytokine expression in BAL fluid from CD8-deficient recipients.

CD8-deficient mice were initially sensitized and challenged and received no cells (OVA/OVA), 4×10^5 CD8⁺ T cells differentiated in IL-2+IL-4 under normoxia (OVA/OVA + Tc2_Normoxia) or 4×10^5 CD8⁺ T cells differentiated in IL-2+IL-4 under hypoxia (OVA/OVA + Tc2_Hypoxia) prior to secondary challenge. As controls, CD8-deficient recipients were not initially sensitized but challenged only and received no cells (PBS/OVA) or 4×10^5 CD8⁺ T cells differentiated in IL-2+IL-4 under normoxia (PBS/OVA + Tc2_Normoxia) prior to secondary challenge. BAL fluid was obtained 48 hrs after the final challenge and cytokine levels were determined by ELISA.

Results are from 2 independent experiments with 8 mice/group. ns: not significant, ND: not detectable.

Figure S3: Lineage-specific transcription factor mRNA expression in CD8⁺ T cells.

Hif-1 α , *Gata3*, and *Tbx21* mRNA expression was monitored by quantitative RT-PCR in CD8⁺ T cells differentiated in IL-2 or IL-2+IL-4 under normoxia or hypoxia for 4 days. Data (means $\pm$ SEM) are from 5 independent experiments. (A) *Hif-1 α* , (B) *Gata3*, and (C) *Tbx21* mRNA levels.

Figure S4: pSTAT6 protein levels after hypoxia treatment.

OT1 cells were cultured in the presence of IL-2+IL-4 under hypoxia for 1hr, 4hr and 24hr followed by intracellular staining for pSTAT6. OT1 cells (0 hr) were used as controls. All cells were gated on CD3⁺CD8⁺ populations. All the histograms are presented half offset.

Figure S5: Tc2 differentiation and *Hif-1 α* mRNA expression in CD8⁺ T cells following inhibition of JAK1/3 and silencing of *GATA3*.

(A) CD8⁺ T cells were differentiated *in vitro* for 4 days in the presence of IL-2+IL-4 followed by SIINFEKL re-stimulation. Intracellular staining for IL-13 was carried out in CD8⁺ T cells treated with DMSO, or 25, 50, or 100 nM of the JAK inhibitor (JAKi). Percentages of IL-13 single-positive cells from 5 independent experiments are shown. **p<0.01, compared to cells differentiated in DMSO. (B) *Hif-1 α* mRNA

expression was monitored by quantitative RT-PCR in CD8⁺ T cells differentiated in the presence of IL-2+IL-4 and the JAKi followed by SIINFEKL re-stimulation. * $p < 0.05$, ** $p < 0.01$ compared to cells differentiated in DMSO. (C) CD8⁺ T cells were transduced with retrovirus expressing scrambled shRNA or GATA3 shRNA. Intracellular staining for IL-13 expression in sorted GFP⁺ transfected cells were analyzed. Percentages of IL-13-positive cells from 3 independent experiments are shown. * $p < 0.05$. (D) *Hif-1 α* mRNA levels in GFP⁺ cells following transduction with scrambled shRNA or GATA3 shRNA. Data (mean $\pm$ SEM) are from 3 independent experiments. * $p < 0.05$.

Figure S6: HIF-1 α protein levels in CD8⁺ T cells from HIF-1 α -deficient mice.

(A) HIF-1 α protein levels detected by immunoblot analysis. (B) Quantitative densitometry of autoradiographs from WT and HIF-1 α -deficient CD8⁺ T cells (HIF KO) differentiated in IL-2+IL-4 for 4 days. Relative density of WT T cells was assigned a value of 1. A representative result is shown from 3 independent experiments with similar results demonstrating a reduction of 85 $\pm$ 6% reduction in HIF-1 α protein levels in HIF KO cells.

Figure S7: IFN γ expression in differentiated HIF-1 α -deficient CD8⁺ T cells.

CD8⁺ T cells from Lck-Cre/OT-1 (WT) and HIF-1 α -deficient Lck-Cre/HIF1 α^{flox} /OT-1 (HIF KO) mice were differentiated *in vitro* in the presence of IL-2 followed by SIINFEKL re-stimulation. IFN γ protein levels in cells differentiated in IL-2 under

normoxia or hypoxia after SIINFEKL re-stimulation. Data (means $\pm$ SEM) are from 5 independent experiments.